Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clara De Simone

Showing results (181-190 of 213) with videos related to

Pageof 22
Sort By:
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Dermatology Practical & Conceptual|November 14, 2025
GRINCH Index: Measuring Patient Satisfaction During Christmas Holiday Gift ProgramsGiulio Gualdi, Laura Bigi, Clara De Simone, et al.
Psoriasis (Auckland, N.Z.)|September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Expert Opinion on Biological Therapy|June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 yearMarco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
Journal of the American Academy of Dermatology|March 3, 2022
Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter studyAdele Salemme, Luca Fania, Alessandra Scarabello, et al.
Dermatology and Therapy|April 16, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology|April 16, 2025
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
European Journal of Dermatology : EJD|March 2, 2021
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasisAndrea Chiricozzi, Antonio Costanzo, Maria Concetta Fargnoli, et al.
Frontiers in Medicine|August 7, 2023
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experienceMartina Merli, Martina Accorinti, Maurizio Romagnuolo, et al.
Clinical and Experimental Dermatology|October 10, 2025
VARIANT_P: a 14-years multicentric follow-up study of atypical pemphigus variants in ItalyLavinia Quintarelli, Irene Bonanni, Elena Biancamaria Mariotti, et al.
Pageof 22

Showing results (181-190 of 213) with videos related to

Sort By:
Pageof 22
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Dermatology Practical & Conceptual|November 14, 2025
GRINCH Index: Measuring Patient Satisfaction During Christmas Holiday Gift ProgramsGiulio Gualdi, Laura Bigi, Clara De Simone, et al.
Psoriasis (Auckland, N.Z.)|September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Expert Opinion on Biological Therapy|June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 yearMarco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
Journal of the American Academy of Dermatology|March 3, 2022
Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter studyAdele Salemme, Luca Fania, Alessandra Scarabello, et al.
Dermatology and Therapy|April 16, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology|April 16, 2025
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
European Journal of Dermatology : EJD|March 2, 2021
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasisAndrea Chiricozzi, Antonio Costanzo, Maria Concetta Fargnoli, et al.
Frontiers in Medicine|August 7, 2023
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experienceMartina Merli, Martina Accorinti, Maurizio Romagnuolo, et al.
Clinical and Experimental Dermatology|October 10, 2025
VARIANT_P: a 14-years multicentric follow-up study of atypical pemphigus variants in ItalyLavinia Quintarelli, Irene Bonanni, Elena Biancamaria Mariotti, et al.
Pageof 22